B-intervention	0	4	High
I-intervention	4	5	-
I-intervention	5	9	dose
I-intervention	10	22	chemotherapy
O	23	27	with
O	28	41	hematopoietic
O	42	46	stem
O	46	47	-
O	47	51	cell
O	52	58	rescue
O	59	62	for
O	63	67	high
O	67	68	-
O	68	72	risk
O	73	79	breast
O	80	86	cancer
O	86	87	.

O	88	91	The
O	92	95	use
O	96	98	of
O	99	103	high
O	103	104	-
O	104	108	dose
O	109	117	adjuvant
O	118	130	chemotherapy
O	131	134	for
O	135	139	high
O	139	140	-
O	140	144	risk
O	145	152	primary
O	153	159	breast
O	160	166	cancer
O	167	169	is
O	170	183	controversial
O	183	184	.

O	185	187	We
O	188	195	studied
O	196	199	its
O	200	208	efficacy
O	209	211	in
O	212	220	patients
O	221	225	with
O	226	227	4
O	228	230	to
O	231	232	9
O	233	235	or
O	236	238	10
O	239	241	or
O	242	246	more
O	247	252	tumor
O	252	253	-
O	253	261	positive
O	262	270	axillary
O	271	276	lymph
O	277	282	nodes
O	282	283	.

O	284	292	Patients
B-age	293	300	younger
I-age	301	305	than
I-age	306	308	56
I-age	309	314	years
O	315	317	of
O	318	321	age
B-eligibility	322	325	who
I-eligibility	326	329	had
I-eligibility	330	339	undergone
I-eligibility	340	347	surgery
I-eligibility	348	351	for
I-eligibility	352	358	breast
I-eligibility	359	365	cancer
I-eligibility	366	369	and
I-eligibility	370	373	who
I-eligibility	374	377	had
I-eligibility	378	380	no
I-eligibility	381	388	distant
I-eligibility	389	399	metastases
O	400	404	were
O	405	413	eligible
O	414	416	if
O	417	421	they
O	422	425	had
O	426	428	at
O	429	434	least
O	435	439	four
O	440	445	tumor
O	445	446	-
O	446	454	positive
O	455	463	axillary
O	464	469	lymph
O	470	475	nodes
O	475	476	.

O	477	485	Patients
O	486	488	in
O	489	492	the
O	493	505	conventional
O	505	506	-
O	506	510	dose
O	511	516	group
O	517	525	received
O	526	538	fluorouracil
O	538	539	,
O	540	550	epirubicin
O	550	551	,
O	552	555	and
O	556	572	cyclophosphamide
O	573	574	(
O	574	577	FEC
O	577	578	)
O	579	584	every
O	585	590	three
O	591	596	weeks
O	597	600	for
O	601	605	five
O	606	613	courses
O	613	614	,
O	615	623	followed
O	624	626	by
O	627	639	radiotherapy
O	640	643	and
O	644	653	tamoxifen
O	653	654	.

O	655	658	The
O	659	663	high
O	663	664	-
O	664	668	dose
O	669	678	treatment
O	679	682	was
O	683	692	identical
O	692	693	,
O	694	700	except
O	701	705	that
O	706	710	high
O	710	711	-
O	711	715	dose
O	716	728	chemotherapy
O	729	730	(
O	730	731	6
O	732	733	g
O	734	736	of
O	737	753	cyclophosphamide
O	754	757	per
O	758	764	square
O	765	770	meter
O	771	773	of
O	774	778	body
O	778	779	-
O	779	786	surface
O	787	791	area
O	791	792	,
O	793	796	480
O	797	799	mg
O	800	802	of
O	803	811	thiotepa
O	812	815	per
O	816	822	square
O	823	828	meter
O	828	829	,
O	830	833	and
O	834	838	1600
O	839	841	mg
O	842	844	of
O	845	856	carboplatin
O	857	860	per
O	861	867	square
O	868	873	meter
O	873	874	)
O	875	879	with
O	880	890	autologous
O	891	901	peripheral
O	901	902	-
O	902	907	blood
O	908	921	hematopoietic
O	922	932	progenitor
O	932	933	-
O	933	937	cell
O	938	953	transplantation
O	954	962	replaced
O	963	966	the
O	967	972	fifth
O	973	979	course
O	980	982	of
O	983	986	FEC
O	986	987	.

O	988	990	Of
O	991	994	the
B-total-participants	995	998	885
O	999	1007	patients
O	1007	1008	,
B-intervention-participants	1009	1012	442
O	1013	1017	were
O	1018	1026	assigned
O	1027	1029	to
O	1030	1033	the
O	1034	1038	high
O	1038	1039	-
O	1039	1043	dose
O	1044	1049	group
O	1050	1053	and
B-control-participants	1054	1057	443
O	1058	1060	to
O	1061	1064	the
B-control	1065	1077	conventional
I-control	1077	1078	-
I-control	1078	1082	dose
I-control	1083	1088	group
O	1088	1089	.

O	1090	1095	After
O	1096	1097	a
O	1098	1104	median
O	1105	1111	follow
O	1111	1112	-
O	1112	1114	up
O	1115	1117	of
O	1118	1120	57
O	1121	1127	months
O	1127	1128	,
O	1129	1132	the
O	1133	1142	actuarial
B-outcome	1143	1144	5
I-outcome	1144	1145	-
I-outcome	1145	1149	year
I-outcome	1150	1157	relapse
I-outcome	1157	1158	-
I-outcome	1158	1162	free
I-outcome	1163	1171	survival
I-outcome	1172	1177	rates
O	1178	1182	were
B-cv-bin-percent	1183	1185	59
I-cv-bin-percent	1186	1193	percent
O	1194	1196	in
O	1197	1200	the
O	1201	1213	conventional
O	1213	1214	-
O	1214	1218	dose
O	1219	1224	group
O	1225	1228	and
B-iv-bin-percent	1229	1231	65
I-iv-bin-percent	1232	1239	percent
O	1240	1242	in
O	1243	1246	the
O	1247	1251	high
O	1251	1252	-
O	1252	1256	dose
O	1257	1262	group
O	1263	1264	(
O	1264	1270	hazard
O	1271	1276	ratio
O	1277	1280	for
O	1281	1288	relapse
O	1289	1291	in
O	1292	1295	the
O	1296	1300	high
O	1300	1301	-
O	1301	1305	dose
O	1306	1311	group
O	1311	1312	,
O	1313	1314	0
O	1314	1315	.
O	1315	1317	83
O	1317	1318	;
O	1319	1321	95
O	1322	1329	percent
O	1330	1340	confidence
O	1341	1349	interval
O	1349	1350	,
O	1351	1352	0
O	1352	1353	.
O	1353	1355	66
O	1356	1358	to
O	1359	1360	1
O	1360	1361	.
O	1361	1363	03
O	1363	1364	;
O	1365	1366	P
O	1366	1367	=
O	1367	1368	0
O	1368	1369	.
O	1369	1371	09
O	1371	1372	)
O	1372	1373	.

O	1374	1376	In
O	1377	1380	the
O	1381	1386	group
O	1387	1391	with
O	1392	1394	10
O	1395	1397	or
O	1398	1402	more
O	1403	1411	positive
O	1412	1417	nodes
O	1417	1418	,
O	1419	1422	the
B-outcome	1423	1430	relapse
I-outcome	1430	1431	-
I-outcome	1431	1435	free
I-outcome	1436	1444	survival
I-outcome	1445	1450	rates
O	1451	1455	were
B-cv-bin-percent	1456	1458	51
I-cv-bin-percent	1459	1466	percent
O	1467	1469	in
O	1470	1473	the
O	1474	1486	conventional
O	1486	1487	-
O	1487	1491	dose
O	1492	1497	group
O	1498	1501	and
B-iv-bin-percent	1502	1504	61
I-iv-bin-percent	1505	1512	percent
O	1513	1515	in
O	1516	1519	the
O	1520	1524	high
O	1524	1525	-
O	1525	1529	dose
O	1530	1535	group
O	1536	1537	(
O	1537	1538	P
O	1538	1539	=
O	1539	1540	0
O	1540	1541	.
O	1541	1543	05
O	1544	1546	by
O	1547	1550	the
O	1551	1554	log
O	1554	1555	-
O	1555	1559	rank
O	1560	1564	test
O	1564	1565	;
O	1566	1572	hazard
O	1573	1578	ratio
O	1579	1582	for
O	1583	1590	relapse
O	1590	1591	,
O	1592	1593	0
O	1593	1594	.
O	1594	1596	71
O	1596	1597	;
O	1598	1600	95
O	1601	1608	percent
O	1609	1619	confidence
O	1620	1628	interval
O	1628	1629	,
O	1630	1631	0
O	1631	1632	.
O	1632	1634	50
O	1635	1637	to
O	1638	1639	1
O	1639	1640	.
O	1640	1642	00
O	1642	1643	)
O	1643	1644	.

O	1645	1649	High
O	1649	1650	-
O	1650	1654	dose
O	1655	1665	alkylating
O	1666	1673	therapy
O	1674	1682	improves
B-outcome	1683	1690	relapse
I-outcome	1690	1691	-
I-outcome	1691	1695	free
I-outcome	1696	1704	survival
O	1705	1710	among
O	1711	1719	patients
O	1720	1724	with
O	1725	1730	stage
O	1731	1733	II
O	1734	1736	or
O	1737	1740	III
O	1741	1747	breast
O	1748	1754	cancer
O	1755	1758	and
O	1759	1761	10
O	1762	1764	or
O	1765	1769	more
O	1770	1778	positive
O	1779	1787	axillary
O	1788	1793	lymph
O	1794	1799	nodes
O	1799	1800	.

O	1801	1805	This
O	1806	1813	benefit
O	1814	1817	may
O	1818	1820	be
O	1821	1829	confined
O	1830	1832	to
O	1833	1841	patients
O	1842	1846	with
O	1847	1850	HER
O	1850	1851	-
O	1851	1852	2
O	1852	1853	/
O	1853	1856	neu
O	1856	1857	-
O	1857	1865	negative
O	1866	1872	tumors
O	1872	1873	.
